There was strong uptake of Rybrevant-Lazcluze in first-line advanced, EGFR-mutated NSCLC after the combo bested AstraZeneca's Tagrisso in the MARIPOSA trial.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback